This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: C00 (Malignant neoplasm of lip) | Special Copayment Reduction: V193 (reduced copayment for care of the relevant condition for 5 years from the registration date of a registered cancer patient) |
| B. Synonyms | Lip cancer, cancer of the lip, lower lip cancer, upper lip cancer, squamous cell carcinoma of the lip, Lip carcinoma, Squamous cell carcinoma of the lip, Cancer of the lip, Lip SCC, Carcinoma of the vermilion border |
| C. Adult onset | Likelihood of first onset in adulthood very high — more than 84% of patients are diagnosed after age 45, peaking in their 60s–70s. Typically, cumulative risk factors such as chronic ultraviolet exposure, smoking, and alcohol act over a long period and the disease first appears in mid-to-late adulthood; onset in children and adolescents is extremely rare. |
| 1. History | Ancient Egyptian and Greek medical records → 19th-century dermatologic classification → recognition of ultraviolet carcinogenesis in the 1920s → Karapandzic flap technique in 1974 → establishment of molecular pathology in the 1990s → expansion of Mohs surgery and immunotherapy since the 2000s. |
| 2. Causes | Main causes: chronic ultraviolet exposure (mainly lower lip), smoking (especially pipe smoking), alcohol. Ancillary risk factors: HPV infection (some cases), immunosuppression, long-term use of hydrochlorothiazide, occupational UV exposure (agricultural, fishing, and outdoor workers), fair skin phenotype (Fitzpatrick types I–II). |
| 3. Genetics | TP53 mutations (including the UV signature CC→TT transition) are the most frequent. Loss of heterozygosity (LOH) at 9p, 9q, and 17p, CDKN2A inactivation, AURKA/AURKB amplification, PTEN deletion, and MYC rearrangement have been reported. BRAF V600E mutation not detected. No hereditary predisposition. |
| 4. General epidemiology | Accounts for 25–30% of all oral and maxillofacial tumors. Male:female ≈ 1.7:1. 84.8% aged 45 or older. More than 90% arise on the lower lip. Korea: about 0.2% of all cancers, about 1 per 100,000 population. By age: 60s 27%, 70s 26%. More than 90% are squamous cell carcinoma histologically. |
| 5. Pathophysiology | Chronic UV-B irradiation → formation of pyrimidine dimers (CPD, 6-4PP) → impaired DNA repair → accumulation of TP53 mutations → dysregulated cell proliferation. Actinic cheilitis acts as a precancerous lesion, with the risk of malignant transformation increasing with the degree of dysplasia. |
| 6. Symptoms | Early: painless erythematous or white papule/ulcer. With progression: firm ulcerative lesion, bleeding, crust formation. Late: pain, difficulty opening the mouth, speaking, and swallowing, numbness. Most lesions are located in the central vermilion of the lower lip. |
| 7. Signs | Indurated ulcer of the vermilion with irregular margins. Infiltration into adjacent skin or oral mucosa. Enlargement of submandibular and submental lymph nodes on the affected side. A solid mass that is painless or mildly tender on palpation. With concurrent actinic cheilitis, dryness, fissuring, and peeling of the lip as a whole. |
| 8. Screening | No population-wide screening program. High-risk groups (outdoor workers, long-term smokers and drinkers, immunosuppressed patients): regular oral inspection and palpation every 6–12 months. Biopsy when actinic cheilitis is identified. Adjunctive tools: VELscope, toluidine blue vital staining. |
| 9. Diagnosis | Histologic confirmation by incisional biopsy. Staging: CT (neck, chest), MRI (soft tissue, perineural invasion), PET-CT (distant metastasis). TNM stage (AJCC 8th edition): T1 (≤2 cm), T2 (>2–4 cm), T3 (>4 cm), T4 (invasion of adjacent structures). N stage: N0–N3. |
| 10. Treatment | First-line: wide excision (wedge excision, Karapandzic/Abbe flap reconstruction). High-risk/close-positive margins: combined postoperative radiation. Unresectable/advanced: cisplatin-based concurrent chemoradiotherapy. EGFR expression positive: add cetuximab. Advanced/recurrent: immune checkpoint inhibitors (pembrolizumab, nivolumab). |
| 11. Prognosis | 5-year overall survival about 90% (localized stage ~94%). Falls to about 69% with lymph node metastasis. Main prognostic factors: stage, histologic differentiation, lymph node metastasis, perineural invasion, margin status. Prognosis is favorable with early detection and active treatment. Recurrence is concentrated within 2 years after treatment. |
| 12. Prevention | Primary: SPF ≥30 sunscreen lip balm/sunscreen, wide-brimmed hat, smoking cessation, moderation of alcohol intake. Secondary: early treatment of actinic cheilitis (laser removal, topical 5-FU/imiquimod). Tertiary: regular oral examination every 6–12 months, maintenance of oral hygiene after dental treatment. |
| 13. References | Scuderi N et al. Lip Cancer: A 10-Year Retrospective Epidemiological Study. Anticancer Res. 2012 … and 9 other papers |
Malignant lesions of the lips were observed quite early in the history of medicine. The ancient Egyptian Ebers Papyrus (about 1550 BC) contains fragmentary descriptions of oral lesions including the lips, and in the 5th century BC Hippocrates mentioned ulcerative lesions in the mouth and described various masses arising in the skin and mucosa. However, lip cancer was clearly classified as an independent disease entity only after the development of modern pathology.
In 18th–19th-century Europe, clinical understanding of head and neck cancers advanced rapidly. The British surgeon Percivall Pott first described in 1775 the causal relationship between scrotal cancer in chimney sweeps and soot exposure, and this concept linking environmental exposure with cancer development gradually began to be applied to lip lesions as well. In the mid-19th century, clinicians repeatedly reported an association between pipe smoking and lower lip ulcers, and attention was drawn to the frequency of chronic ulcers and masses of the lower lip in men who worked outdoors for long hours, such as sailors, farmers, and fishermen.
In 1907, the German pathologist Paul Gerson Unna proposed the important concept that chronic sun exposure causes cellular damage in skin and lip lesions of sailors, and the "Seamen's skin" he described is recognized today as the forerunner of actinic keratosis and actinic cheilitis. As studies proving in animal experiments that ultraviolet light directly causes cancer were published through the 1920s–30s, scientific evidence was established that UV irradiation plays a key role in the development of lip cancer.
In the history of surgical treatment, various procedures for excision and reconstruction of lip lesions were developed from the late 19th century. In 1872, Robert Abbe first described the upper–lower lip cross flap (Abbe flap), and in 1904 Jacob August Estlander published a flap procedure specialized for reconstructing defects including the oral commissure. In 1974, the Yugoslav surgeon Miodrag Karapandzic described a rotation-advancement flap that reconstructs large lower lip defects while preserving the neurovascular supply, making functionally and cosmetically superior reconstruction possible.
In the era of molecular biology, understanding of the pathogenesis of lip cancer deepened dramatically. Since the 1990s, mutations of the TP53 tumor suppressor gene have been identified as the 'molecular signature' of UV damage, and loss of heterozygosity (LOH) on chromosomes 9p and 9q was shown to be an early molecular event in lip cancer. In the 2000s, Mohs micrographic surgery was applied to squamous cell carcinoma of the lip and was reported to offer tissue-sparing benefits with recurrence rates similar to conventional wide excision. Recently, as EGFR-targeted therapy (cetuximab) and immune checkpoint inhibitors (pembrolizumab, nivolumab) have become standard treatments for advanced/recurrent head and neck squamous cell carcinoma, new treatment options are expanding even for unresectable lip cancer.
In Korea, lip cancer is a relatively rare cancer accounting for about 0.2% of all cancer cases, and its epidemiology is continuously monitored through registry data from the National Cancer Center and the Health Insurance Review & Assessment Service (HIRA). With application of the Special Copayment Reduction code V193, registered patients have a reduced treatment cost burden, and multidisciplinary treatment approaches are becoming standardized, centered on specialized head and neck cancer centers.
Malignant neoplasm of the lip (lip cancer) arises from the combined action of multiple risk factors rather than a single cause. Characteristically, the relative weight of causes differs by site of origin, and there are meaningful differences in causative factors between lower lip cancer and upper lip cancer.
Ultraviolet (UV) exposure: the most important cause of lip cancer, especially squamous cell carcinoma of the lower lip. Because the lower lip vermilion is more directly exposed to solar ultraviolet radiation than the upper lip, more than 90% of lip cancers arise on the lower lip. UV-B (280–320 nm) forms dimers (cyclobutane pyrimidine dimers, CPD) and 6-4 photoproducts (6-4 PP) between adjacent pyrimidine bases in DNA, inducing TP53 gene mutations. The greater the chronic cumulative UV exposure, the higher the risk, and incidence is markedly higher among outdoor workers in agriculture, fishing, construction, and similar occupations.
Smoking: the second major risk factor for lip cancer; pipe smoking in particular shows a strong association with the lower lip, the direct contact surface. Carcinogens in tobacco smoke such as polycyclic aromatic hydrocarbons (PAH), nitrosamines, and formaldehyde directly damage the DNA of labial mucosal cells. In large epidemiologic studies, smokers have about 2–4 times the risk of lip cancer compared with nonsmokers, and the risk rises in a dose-response relationship with increasing amount and duration of smoking.
Alcohol: smoking and alcohol intake show a synergistic effect across head and neck cancers. The cytotoxicity of alcohol itself, the DNA-damaging effect of its metabolite acetaldehyde, and nutritional deficiencies due to alcohol intake (folate and vitamin B deficiency) act in combination. The risk from drinking alone is lower than that of smoking, but combined with smoking, the risk of lip and oral cancer becomes much higher than the sum of their individual effects.
Actinic cheilitis: a precancerous lesion caused by chronic UV exposure, characterized by dryness, fissuring, peeling, erythema, and white patches of the lower lip vermilion. The annual malignant transformation rate in patients with actinic cheilitis is estimated at about 1–2%, and the risk increases with higher grades of dysplasia. Actinic cheilitis is a direct precursor lesion of lip cancer, and recognizing and treating it early is central to prevention.
Human papillomavirus (HPV): while the role of HPV (especially types 16 and 18) is well established in pharyngeal and tonsillar cancers, its direct carcinogenic role in lip cancer is relatively unclear. Some studies detected HPV DNA in about 10–25% of lip squamous cell carcinoma tissues, but its role in UV-induced lip cancer is considered more limited than in oropharyngeal cancer.
Immunosuppression: the risk of lip cancer increases markedly in immunosuppressed states such as solid organ transplant recipients, people with HIV infection, and patients with hematologic malignancies. In transplant patients, the incidence of nonmelanoma skin cancer and lip cancer is tens of times higher than in the general population, owing to the combined effects of the carcinogenicity of immunosuppressants such as cyclosporine and azathioprine and impaired immune surveillance.
Hydrochlorothiazide (HCTZ): a recent large Danish cohort study reported a significantly increased risk of lip and skin squamous cell carcinoma in long-term HCTZ users. This is explained by the photosensitizing effect of HCTZ, which amplifies UV-induced DNA damage.
Lip cancer has no clear hereditary predisposition and is a sporadic malignancy arising mostly from the accumulation of somatic mutations caused by environmental factors (especially UV). However, the pattern of molecular genetic changes within the tumor is similar to other head and neck squamous cell carcinomas and cutaneous squamous cell carcinomas, while showing features specific to the lip.
TP53 tumor suppressor gene mutations: the most frequently reported molecular abnormality in lip cancer and its precursor lesion, actinic cheilitis. TP53 mutations are found in about 40–60% of lip cancers, and notably a substantial portion of them show a UV-specific mutational signature (UV mutational signature, Signature 7) including CC→TT transitions. This is molecular evidence strongly supporting that lip cancer arises from direct DNA damage caused by UV-B irradiation. TP53 variants cause loss of cell-cycle arrest and apoptotic function, allowing damaged cells to continue proliferating.
Loss of heterozygosity (LOH): a high frequency of LOH has been reported in lip cancer and actinic cheilitis on the short arm (9p) and long arm (9q) of chromosome 9 and the short arm of chromosome 17 (17p). The cell-cycle regulator CDKN2A (p16, INK4a) is located at 9p21, and inactivation of this gene is considered one of the early molecular events in lip cancer. Loss of p16 increases Rb phosphorylation through CDK4/6 activation, promoting the G1/S transition. LOH at 9q is presumed to be related to loss of as yet unidentified genes with tumor suppressor function.
Aurora kinase amplification: recent studies of lower lip squamous cell carcinoma reported that gene amplification of AURKA (Aurora kinase A) and AURKB (Aurora kinase B) is markedly higher in lip squamous cell carcinoma than in actinic cheilitis. Aurora kinases play a key role in regulating mitosis, and their overexpression increases chromosomal instability, aneuploidy, and tumor invasiveness. Aurora kinase inhibitors are currently under clinical investigation in solid tumors including head and neck cancer.
PTEN deletion and PI3K/AKT pathway activation: activation of the PI3K/AKT/mTOR pathway is frequently reported across head and neck squamous cell carcinomas, and in lip cancer abnormalities of this pathway due to PTEN deletion are also observed. PTEN deletion promotes cell survival, proliferation, and invasion, and is being studied as a therapeutic target for mTOR inhibitors (everolimus, etc.).
EGFR overexpression and MYC amplification: EGFR (epidermal growth factor receptor) is overexpressed in about 80–90% of head and neck squamous cell carcinomas, and a similar pattern is observed in lip cancer. EGFR overexpression activates RAS/MAPK and PI3K/AKT signaling, promoting cell proliferation and survival. MYC rearrangement is also detected in some lip squamous cell carcinomas and is associated with tumor progression. BRAF V600E mutations are not detected in lip cancer or actinic cheilitis, which helps in molecular differentiation from melanoma.
DNA damage repair genes and the tumor microenvironment: changes in the expression of DNA damage repair proteins such as APE1, hMSH2, and ERCC1 have been reported to be involved in the malignant progression of lip cancer. Increased immunohistochemical expression of 8-hydroxy-2'-deoxyguanosine (8-OHdG) suggests that DNA damage due to oxidative stress is actively progressing even in actinic cheilitis. In the tumor microenvironment, the degree of infiltration by CD8+ cytotoxic T cells and PD-L1 expression are being studied as predictors of response to immune checkpoint inhibitor therapy.
Lip cancer accounts for a substantial share of head and neck malignancies worldwide, making up about 25–30% of tumors of the oral and maxillofacial region. The annual incidence of lip cancer worldwide varies greatly by region, race, and climate zone, and incidence is markedly higher in regions with strong sunshine and a high proportion of outdoor workers. Southern Italy, Spain, Portugal, Brazil, Australia, New Zealand, and India are among the countries with relatively high incidence.
Sex: lip cancer shows a clear male predominance. In a 10-year retrospective epidemiologic study in Italy (Scuderi et al., 2012, n=540), men accounted for 82%. Data from the Korean National Cancer Information Center also report a male-to-female ratio of about 1.7:1. The male predominance has traditionally been attributed to sex differences in outdoor employment and smoking rates, but the gap has been narrowing somewhat recently with increased outdoor activity and smoking among women.
Age: people aged 45 or older account for 84.8% of all patients, and incidence continues to rise with age. In the Korean age distribution, people in their 60s account for about 27%, 70s about 26%, and 50s about 20%. The mean age at diagnosis is about 60–65 years, reflecting the nature of a disease that develops only after cumulative ultraviolet exposure builds up over decades.
Site of origin: more than 90% of lip cancers arise on the lower lip, because the lower lip vermilion is more exposed to the direction of sunlight than the upper lip. Lesions are mostly located in the central part (middle third) of the lower lip vermilion or lateral to it, and involvement of the commissure is relatively rare. Upper lip cancer accounts for only 5–10% of all lip cancers, and among cancers arising on the upper lip the proportion of basal cell carcinoma (BCC) is relatively high.
Histologic type: about 90–95% of lip cancers are squamous cell carcinoma (SCC). Other types that rarely occur include verrucous carcinoma, spindle cell carcinoma, basal cell carcinoma (BCC, relatively more common on the upper lip), melanoma, and mucoepidermoid carcinoma of salivary gland origin.
Epidemiology in Korea: according to Korea Central Cancer Registry data, lip cancer accounts for about 0.2% of all cancers in Korea, with a crude incidence of about 1 per 100,000 population. Because of its low frequency, it is often not presented as a separate item in cancer statistics and is instead included in the 'oral cavity and pharyngeal cancer' category. The Special Copayment Reduction code V193 (reduced copayment for care of the relevant condition for 5 years after cancer patient registration) applies.
Mortality and incidence trends: according to the US SEER database (2000–2019), the age-adjusted incidence of SCC of the lip has generally decreased or remained stable, which is associated with rising smoking cessation rates and improved public awareness of sun protection. However, with the growing immunosuppressed population (organ transplant recipients, etc.), incidence tends to increase in some vulnerable groups.
The pathogenesis of lip cancer, especially lower lip squamous cell carcinoma, is understood as a multistep carcinogenic process involving DNA damage caused by ultraviolet (UV) irradiation and passing through the precursor lesion actinic cheilitis.
UV irradiation and DNA damage: UV-B (280–320 nm) in solar ultraviolet radiation is directly absorbed by DNA in the nuclei of lip vermilion epithelial cells, forming cyclobutane pyrimidine dimers (CPD) and 6-4 photoproducts (6-4 PP) between adjacent pyrimidine bases (thymine–thymine, thymine–cytosine, cytosine–cytosine). These DNA cross-linked structures interfere with normal DNA replication and transcription. Cells repair most of the damage by the nucleotide excision repair (NER) mechanism, but when the damage exceeds repair capacity or the repair mechanism itself is impaired, mutations become fixed.
TP53 mutation and cell-cycle dysregulation: the most representative molecular consequence of UV damage is TP53 mutation. UV-induced CC→TT transitions (a special form of C→T transition) cause missense mutations in the functional domains of the p53 protein, impairing its functions of DNA damage sensing, induction of G1 cell-cycle arrest, and activation of apoptosis. Cells that have lost p53 function do not stop proliferating despite DNA damage and become vulnerable to the accumulation of additional genetic abnormalities. In addition, CDKN2A (p16) inactivation overactivates CDK4/6, releasing the E2F transcription factor through phosphorylation of Rb (retinoblastoma protein) and promoting entry into the S phase of the cell cycle.
Malignant transformation from actinic cheilitis to lip cancer: actinic cheilitis (AC) is a precancerous lesion caused by chronic UV exposure of the lower lip vermilion, clinically showing mixed findings of dryness, fissuring, peeling, white patches, or erythema. Histologically, epithelial dysplasia is classified as mild, moderate, or severe, and progresses through carcinoma in situ to invasive squamous cell carcinoma. The malignant transformation rate of actinic cheilitis is estimated at about 1–2% per year, and the risk of transformation increases with higher dysplasia grade. During this process, TP53 mutation, p16 loss, EGFR overexpression, and reduced DNA repair capacity accumulate stepwise.
Epithelial-mesenchymal transition (EMT) and invasion: upon transformation to invasive squamous cell carcinoma, E-cadherin expression decreases and mesenchymal markers such as N-cadherin, vimentin, and fibronectin are upregulated, so epithelial cells acquire motility and invasiveness. Secretion of MMPs (matrix metalloproteinases), which degrade type I and IV collagen of the basement membrane, increases, and VEGF secretion for angiogenesis also rises, opening pathways for the tumor to invade the surrounding connective tissue, muscle, and perineural tissue.
Mechanism of lymph node metastasis: the primary lymphatic drainage of lip cancer is to the submental and submandibular lymph nodes on the affected (ipsilateral) side, followed by metastasis to the upper deep cervical lymph nodes (Level I, II). In large studies, the rate of lymph node metastasis at first presentation of lip cancer is about 5–15%, lower than for other cancers of the oral cavity. This is because the density of lymphatics beneath the lip vermilion is relatively low and the tumor can be found quickly on inspection at the surface. However, the risk of lymph node metastasis increases markedly with T3/T4 stage, poor differentiation, or perineural invasion.
Because lip cancer arises in a location easily observed from the outside, early detection is relatively easy, but in many cases it is asymptomatic or causes only mild symptoms early on, so patients themselves overlook it. Symptoms appear stepwise as the stage progresses and often present as changes in pre-existing actinic cheilitis lesions.
Early symptoms: early lip cancer lesions mostly begin as small indurated lesions on the lower lip vermilion without pain or ulceration. Clinically, they may appear in the following forms. The exophytic type protrudes with a rough, wart-like surface, and the ulcerative type shows a shallow ulcer with irregular, indurated margins. If a chronic ulcer or keratotic lesion persists for 4 weeks or more, lip cancer must be suspected. Early on, there is no pain, bleeding, or oral dysfunction, so it is easily confused clinically with simple herpes labialis (HSV), aphthous ulcers, and nonspecific dry lips.
Changes in symptoms with progression: as the lesion progresses, induration becomes pronounced, the ulcer margins become raised, and necrotic tissue may be seen. At this stage, intermittent small amounts of bleeding, crust formation, and local tenderness begin to appear. When the tumor invades toward the oral mucosa, a firm mass is also palpable from inside the mouth. As it extends beyond the central lower lip to the commissure or invades the chin skin, the external size of the lesion becomes noticeably larger.
Advanced symptoms: in advanced lip cancer of stage T3/T4, symptoms include pain (including radiating pain to the face, mouth, and teeth), persistent bleeding or bloody discharge, limited mouth opening (trismus, when the tumor invades the masticatory muscles), abnormal articulation (especially difficulty pronouncing the bilabial sounds b, p, and m), difficulty eating (discomfort chewing and swallowing), and abnormal lip sensation (tingling or numbness, with mental nerve invasion). As invasion of the orbicularis oris muscle progresses, lip movement becomes limited.
Symptoms of concurrent actinic cheilitis: many lip cancer patients have symptoms of actinic cheilitis even before the cancer diagnosis, such as chronic dryness of the lower lip, fissures, peeling, and mixed red-and-white lesions. Patients commonly regard these as simple dry lips and leave them untreated, repeatedly applying lip balm or ointment.
Symptoms of lymph node metastasis: when cervical lymph node metastasis occurs, a painless or mildly tender mass may be felt in the submandibular region (under the jaw), the submental region (below the ear), or the lateral neck. As the lymph nodes enlarge and compress adjacent nerves and vessels, corresponding sensory abnormalities or vascular headaches may occur.
The physical signs of lip cancer vary with stage, tumor size, extent of invasion, and presence of accompanying lesions. An advantage in diagnosing lip cancer is that much information can be obtained from inspection and palpation alone.
Inspection findings of the primary lesion: typical lip squamous cell carcinoma appears as an indurated ulcer or plaque with irregular borders on the lower lip vermilion. The tumor surface is wart-like (verrucous), or the center of the ulcer is covered with necrotic exudate and crust. The ulcer margins (surrounding tissue) are firmer and more raised than normal tissue, and dryness, fissuring, and white patches due to actinic cheilitis are often widely distributed on the vermilion around the tumor. Verrucous carcinoma is a papillary, wart-like exophytic lesion with relatively clearer borders than ordinary SCC, and grows slowly.
Palpation findings: early lip cancer is characterized on palpation by hard, solid induration without tenderness. The less distinct the border with surrounding normal tissue, the wider the extent of invasion. When the tumor invades toward the oral mucosa, a firm mass can also be palpated from the inner side. With invasion of the jawbone (mandibular midline), bony induration is felt on palpation and the tumor feels fixed.
Signs of invasion of adjacent structures: extension to the commissure presents as limited mouth opening (trismus), and with mental nerve invasion, paralysis or hypoesthesia of the lower lip and chin skin (Vincent's sign, lower lip paresthesia) is observed. Mental nerve palsy is an important clinical indicator of nerve involvement within the mandibular marrow or perineural invasion, and a sign of advanced disease.
Cervical lymph node findings: enlargement of submandibular, submental, or upper cervical lymph nodes on neck palpation strongly suggests metastasis. Metastatic lymph nodes are initially mobile but, when adherent to surrounding tissue, are palpated as fixed masses. Firm, fixed lymphadenopathy is a factor that worsens prognosis even when the primary lesion is small.
Special findings: immunosuppressed patients may show multiple lip lesions, rapid increase in size, and atypical forms (such as ulcers without induration). Basaloid differentiation or the spindle cell carcinoma type may show severe surface necrosis and relatively rapid progression in tumor depth.
Items to check when determining clinical stage: systematically check the maximum diameter of the primary lesion (T stage), invasion of the oral mucosa, skin, mandible, and commissure, the size and mobility of ipsilateral and bilateral cervical lymph nodes (Level I–V), the presence of cranial nerve palsy, and systemic symptoms suggesting distant metastasis (weight loss, dyspnea, etc.).
Currently, no population-wide lip cancer screening program for the general population is conducted anywhere in the world. This is because the incidence of lip cancer is relatively low and the lesion is visible to the naked eye from the outside, so early detection is possible by a clinician's inspection alone. However, regular checkups of high-risk groups and the use of adjunctive diagnostic tools are of practical value for the early detection of oral and lip cancer.
Oral examination centered on inspection and palpation: the core of lip cancer screening is oral inspection and palpation by a specialist physician or dentist. It is inexpensive and has the advantage of detecting abnormal lesions clinically without endoscopy. Simply having regular dental checkups every 6–12 months increases the likelihood of detecting early lip cancer. During the examination, the lower lip vermilion, upper lip, intraoral mucosa, tongue, palate, and oropharynx are observed visually and systematically. Particular attention is paid to indurated ulcers, lesions persisting for 4 weeks or more, enlarging lesions, and focal changes in lesions on a background of actinic cheilitis.
Intensive screening of high-risk groups: more intensive screening is recommended in the following high-risk groups: outdoor workers (agriculture, fishing, construction, outdoor sports instructors, etc.), people with a long smoking history, heavy drinkers, immunosuppressed patients (solid organ transplant recipients, people with HIV infection, patients with hematologic malignancies, people on long-term steroids or immunosuppressants), people with a history of actinic cheilitis diagnosis, Fitzpatrick skin types I–II (fair skin), and older men aged 65 or above.
Adjunctive screening tools: some screening tools are used adjunctively in certain clinical settings, but none has been adopted as a standard recommendation. Toluidine blue vital staining selectively binds to the DNA of dysplastic cells and stains lesions blue, which can help define the borders of early lesions that are hard to identify with the naked eye. VELscope (tissue fluorescence examination) shines blue light on the oral mucosa and lips and detects abnormal lesions by loss of the green autofluorescence of normal tissue. However, these tools have high false-positive rates and are not used as stand-alone confirmatory tools; they are used for preliminary assessment before biopsy.
Early management of actinic cheilitis: when actinic cheilitis is identified, the dysplasia grade is confirmed by biopsy, and even for mild dysplasia, active follow-up and preventive treatment (laser resurfacing, CO₂ laser, topical 5-FU, imiquimod cream) are considered. Severe dysplasia or carcinoma in situ is treated by complete excision of the lesion (vermilionectomy). Recognizing actinic cheilitis as a precursor lesion and treating it actively can prevent progression to lip cancer.
Diagnosis of lip cancer consists of three steps: clinical evaluation, histologic confirmation, and radiologic staging. Because the lesion is visible from the outside, the diagnostic process is relatively easy compared with other head and neck cancers, but accurate staging is essential for treatment planning.
Clinical evaluation: take a detailed history of bleeding, time of lesion onset and pattern of change, smoking, drinking, and UV exposure, history of actinic cheilitis, immunosuppressive status, and dental treatment history. Along with a general physical examination, systematically evaluate the size, borders, and induration of the primary lesion, oral and skin invasion, cervical lymph nodes (bilateral), and cranial nerve function (especially lower facial sensation and facial movement).
Biopsy: the key to confirming lip cancer. Incisional biopsy is preferred, sampling tissue including the border (margin) and center of the tumor to assess the invasion pattern and presence of perineural invasion (PNI). For small lesions in which complete excision serves as both diagnosis and treatment, excisional biopsy is also possible. Items to be included in the pathology report: histologic type (SCC vs. other), differentiation (well/moderately/poorly differentiated), depth of invasion (DOI), margin status, perineural invasion, and lymphovascular invasion (LVI). In differentiation grading, poorly differentiated tumors are an independent predictor of lymph node metastasis and recurrence risk.
Imaging: imaging for staging evaluates the size of the primary lesion, extent of invasion of adjacent structures, cervical lymph node metastasis, and distant metastasis. CT (neck and chest): used to evaluate lymph node metastasis (size ≥1 cm, central necrosis, irregular margins, etc.), mandibular invasion (loss of cortical bone/marrow), and distant metastasis to the chest. MRI: with its high soft-tissue resolution, it is advantageous for evaluating perineural invasion (inferior alveolar nerve and mental nerve pathways), invasion of the mandibular marrow, and masticatory muscle invasion. PET-CT: useful for evaluating cervical lymph node metastasis and distant metastasis (lung, liver, bone) and detecting recurrent or residual lesions; considered for high-risk lesions of T2 or higher.
TNM staging (AJCC 8th edition): T (primary tumor) stage: T1 ≤2 cm, T2 >2–4 cm, T3 >4 cm, T4a (invasion of mandible, skin, floor of mouth, facial skin), T4b (invasion of masticator space, pterygoid plates, skull base, or encasement of the carotid artery). N (lymph node) stage: N0 no metastasis, N1 single ipsilateral lymph node ≤3 cm ENE(-), N2 multiple, bilateral, or contralateral, N3 >6 cm or ENE(+). M (distant metastasis): M0/M1. Classified from T1N0M0 (Stage I) to TanyNanyM1 (Stage IVC).
Cervical lymph node biopsy: in clinically N0 patients with high-risk features (T2 or higher, poor differentiation, PNI, LVI), sentinel lymph node biopsy (SLNB) can be used to evaluate potential micrometastasis. When clinically N+ findings are present, metastasis is confirmed by fine-needle aspiration cytology (FNAC) or core needle biopsy.
The key goal of lip cancer treatment is to achieve both complete excision of the primary lesion and functional and cosmetic reconstruction. The treatment plan is decided by comprehensively considering TNM stage, histologic features, the patient's general condition, and the feasibility of surgical reconstruction.
Surgical treatment — excision of the primary lesion: surgery is the first-line treatment for most lip cancers, including squamous cell carcinoma. Securing an adequate safety margin from the lesion border (a grossly negative margin of at least 5–10 mm) is key to preventing recurrence. Intraoperative frozen-section examination of the margins to confirm negative margins is standard. For small lesions (T1, lower lip defect ≤1/3), wedge excision and primary closure are possible. Mohs micrographic surgery has the advantage of minimizing loss of normal tissue while ensuring negative margins in areas requiring tissue sparing or in lesions with indistinct borders.
Surgical treatment — lip reconstruction: various reconstruction procedures are chosen depending on the size and location of the lip defect. If the defect is one-third of the lower lip or less, primary closure is possible. For defects of one-third to one-half of the lower lip, the Abbe flap (cross flap from the upper lip) or Estlander flap (useful for commissure reconstruction) is used. For defects of more than half of the lower lip, the Karapandzic flap is preferred. This flap reconstructs the defect with myocutaneous rotation-advancement flaps including the orbicularis oris from both sides of the face while preserving the neurovascular supply, with the advantage of preserving functional mouth closure and sensation. For extensive defects, free flaps (e.g., radial forearm free flap) or regional flaps are used.
Treatment of the neck: in N0 patients with high-risk features (T2 or higher, poor differentiation, PNI, LVI), ipsilateral neck dissection (Level I–III) is considered. In N+ patients, modified radical neck dissection is performed, and the resected lymph nodes are checked for extranodal extension (ENE).
Radiotherapy: when surgery is not possible or the patient declines surgery, radiotherapy alone can be an alternative, achieving local control rates comparable to surgery for small T1/T2 lesions. Postoperative (adjuvant) radiotherapy is recommended when high-risk pathologic findings (positive margins, ENE, multiple lymph node metastases, PNI, LVI, T4 stage) are present. The standard total dose is 60–66 Gy (local high-risk sites), 1.8–2 Gy per fraction. Intensity-modulated radiotherapy (IMRT) is advantageous for limiting dose to adjacent normal structures (submandibular gland, parotid gland, etc.).
Chemotherapy and combined treatment: for unresectable locally advanced lip cancer or high-risk findings after resection, cisplatin-based concurrent chemoradiotherapy (CCRT) is standard. Cisplatin 40 mg/m² once weekly or 100 mg/m² once every 3 weeks is commonly combined. When cisplatin is difficult to use (reduced renal function, hearing impairment, etc.), carboplatin- or 5-fluorouracil (5-FU)-based regimens can be alternatives.
Targeted therapy and immunotherapy: in EGFR expression-positive cases, cetuximab can be used combined with radiotherapy or alone. For recurrent/metastatic head and neck squamous cell carcinoma, the immune checkpoint inhibitors pembrolizumab and nivolumab have received FDA approval, with superior efficacy in PD-L1 expression-positive (CPS ≥1) patients. As first-line treatment, pembrolizumab alone or combined with 5-FU/platinum-based chemotherapy is also applicable to advanced lip cancer.
Lip cancer has a relatively favorable prognosis among head and neck malignancies. This is because it arises in a location directly visible from the outside, making early detection easy; its rate of cervical lymph node metastasis is lower than that of other oral cancers; and local control rates are high when early-stage disease is treated appropriately.
Overall survival: in large studies including analyses of the US SEER database, the 5-year overall survival of lip cancer is reported at about 88–92%. By stage, 5-year survival reaches about 90–94% for localized stage (Stage I/II) patients, and drops markedly to about 65–75% for locally advanced stage with lymph node metastasis (Stage III) and about 30–50% for stage with distant metastasis (Stage IV).
Major prognostic factors: the most important prognostic factor is stage at diagnosis. In a SEER analysis (2010–2020), localized stage lowered cancer-specific mortality by about 94% compared with distant metastatic stage, and lymph node metastatic stage lowered it by 51%. Histologic differentiation is also an important prognostic factor; poorly differentiated SCC has a high rate of lymph node metastasis and recurs quickly. Perineural invasion (PNI) is an independent poor prognostic factor, significantly increasing the risks of recurrence and distant metastasis. Margin status (positive vs. negative margins after surgery) also has a decisive effect on local recurrence.
Recurrence patterns: most recurrences occur within 2 years after completion of treatment, and locoregional recurrence (primary site or cervical lymph nodes) is much more frequent than distant metastasis. Locoregional recurrence can be treated with salvage therapy by reoperation or radiotherapy, with a 5-year survival of about 50–70% after salvage. When distant metastasis (mainly lung, liver, bone) occurs, the chance of cure decreases, and systemic therapy (chemotherapy, immunotherapy) becomes the main treatment approach.
Prognosis in immunosuppressed patients: lip cancer in immunosuppressed patients (especially organ transplant recipients) tends to show a more aggressive clinical course than in immunocompetent patients. It is characterized by multiple lesions, rapid growth, and high recurrence rates, and the treatment strategy includes adjusting immunosuppressant doses and restoring immune response.
Cancer-related quality of life: because the lips have key functions in eating, speech, and appearance, functional and cosmetic outcomes after treatment directly affect quality of life. The quality of surgical reconstruction (degree of mouth opening, lip symmetry, sensory recovery) and late adverse effects after radiotherapy such as xerostomia, dental caries, and osteoradionecrosis affect long-term quality of life. After completion of cancer treatment, oral rehabilitation, dental care, and psychological support should be provided within a multidisciplinary approach.
Follow-up: regular follow-up after completion of treatment is essential. Generally, inspection and palpation and, if needed, imaging (CT or MRI) are performed every 2–3 months for the first 2 years, every 6 months in years 3–5, and annually thereafter. Continued smoking, heavy drinking, and persistent immunosuppression increase the risk of recurrence and second primary tumors, so follow-up should be accompanied by lifestyle counseling.
Because a substantial part of the causes of lip cancer are attributable to modifiable risk factors such as ultraviolet radiation, smoking, and alcohol, systematic prevention strategies are effective in reducing incidence and preventing malignant transformation of precursor lesions. Prevention is divided into primary (preventing occurrence), secondary (treating precursor lesions), and tertiary (preventing recurrence and second primary cancers) levels.
Primary prevention — sun protection: the most powerful primary prevention strategy for lip cancer is blocking chronic UV exposure. Regularly applying lip balm or sunscreen containing sunscreen ingredients of SPF 30 or higher to the lips is key. Products of SPF 50 or higher provide stronger protection, and broad-spectrum products blocking both UVA and UVB should be chosen. Apply 30 minutes before outdoor activity, reapply every 2 hours, and reapply immediately after it is washed off by water or sweat. Wear a wide-brimmed hat (brim of 7–10 cm or more) to reduce direct sunlight on the face and lips, and minimize unnecessary outdoor exposure between 10 a.m. and 4 p.m. (hours of high UV index). For outdoor workers, UV-protective clothing and continuous lip balm use are emphasized.
Primary prevention — smoking cessation and moderation of alcohol intake: because smoking and drinking are major risk factors for lip and oral cancer, smoking cessation and moderation of alcohol intake play an important role in preventing lip cancer. Over time after quitting smoking, precancerous lesions tend to regress or disappear, and the overall risk of head and neck cancer decreases. Because pipe smoking involves higher exposure of the lips to carcinogens through direct contact than cigars or cigarettes, quitting is especially strongly recommended. Drinking should be limited to less than 14 units per week, and it should be recognized that combining smoking and drinking raises the risk beyond the sum of the individual risks.
Secondary prevention — early treatment of the precursor lesion (actinic cheilitis): because actinic cheilitis is a direct precursor lesion of lip cancer, it is important to detect it early and treat it actively. Nonsurgical treatment options include topical 5-fluorouracil (5-FU) cream (5% or 0.5%), imiquimod 5% cream, and diclofenac 3% gel, which remove precancerous tissue by selectively destroying dysplastic cells or activating the immune response. Procedural treatments include CO₂ laser ablation, cryotherapy, and photodynamic therapy (PDT), and vermilionectomy (lip shave) is the standard treatment for extensive lesions or severe dysplasia.
Secondary prevention — regular oral examinations: high-risk groups (outdoor workers, long-term smokers and drinkers, immunosuppressed patients, people with a history of actinic cheilitis, men aged 65 or older) are advised to have oral inspection and palpation by a dentist or oral and maxillofacial surgeon every 6–12 months. Lip self-examination (regular self-observation using a mirror) can also contribute to early detection of lesions.
Tertiary prevention — prevention of second primary cancers and rehabilitation: even after completion of lip cancer treatment, continued sun protection, smoking cessation, and moderation of alcohol intake are maintained to minimize the risk of second primary cancers. After radiotherapy, patients use fluoride application, artificial saliva, and thorough oral hygiene to prevent xerostomia and dental caries. For rehabilitation of lip function after surgery, oral physical therapy (mouth-opening exercises, lip-strengthening exercises) is performed systematically. For transplant patients, minimizing immunosuppressant doses or switching to agents with lower risk of skin and lip carcinogenesis (e.g., the mTOR inhibitor everolimus) may be discussed with the transplant team.
Scuderi N, Rubino C, Alfano C, et al. Lip cancer: a 10-year retrospective epidemiological study. Anticancer Res. 2012;32(4):1543-1546. PMID: 22493399.
Czerninski R, Zini A, Sgan-Cohen HD. Lip cancer: incidence, trends, histology and survival: 1970–2006. Br J Dermatol. 2010;162(5):1103-1109. DOI: 10.1111/j.1365-2133.2010.09698.x. PMID: 20163430.
Patel SC, Carpenter WR, Tyree S, et al. Increasing incidence of oral tongue squamous cell carcinoma in young white women, age 18 to 44 years. J Clin Oncol. 2011;29(11):1488-1494. DOI: 10.1200/JCO.2010.31.7883. PMID: 21383286.
Czerninski R, Kaplan I, Almoznino G, Maly A, Shalom G. Lip cancer and pre-cancerous lesions harbor TP53 mutations, exhibit allelic loss at 9p, 9q, and 17p, but no BRAF V600E mutations. Tumour Biol. 2015;36(11):8611-8617. DOI: 10.1007/s13277-015-3659-9. PMID: 26084614.
Souza ACDS, Agostini M, Martins MD, et al. Molecular Insights Into Actinic Cheilitis and Lower Lip Squamous Cell Carcinoma: AURKA and AURKB Amplifications and Their Association With Tumor Microenvironment. J Oral Pathol Med. 2025;54(1):e13595. DOI: 10.1111/jop.13595. PMID: 39610218.
Karapandzic M. Reconstruction of lip defects by local arterial flaps. Br J Plast Surg. 1974;27(1):93-97. DOI: 10.1016/0007-1226(74)90198-3. PMID: 4596753.
Agra IMG, Carvalho AL, Pontes E, et al. Postoperative complications after en bloc posterior neck dissection in cancer patients. Head Neck. 2010;32(3):321-326. — (Related reference: SEER Analysis) See also: Danenberg HD, Glotz D, Baran R, et al. Impact of Staging, Histologic Grading, and Racial Background on Lip Cancer Survival in the United States: Insights from the SEER Database (2010–2020). Cancers (Basel). 2025;17(9):1499. DOI: 10.3390/cancers17091499. PMC: PMC12402977.
National Cancer Information Center (NCIC). Lip cancer [Internet]. National Cancer Center; 2019 [last modified June 4, 2019]. URL: https://www.cancer.go.kr
Oral cavity and lip cancer — epidemiology and survival outcomes in southeast Brazil. Fernandes GM, Prado GV, Dedivitis RA, et al. PLoS ONE. 2022;17(5):e0265735. DOI: 10.1371/journal.pone.0265735. PMC: PMC9054163.
Lifestyles, environmental and phenotypic factors associated with lip cancer (case-control, southern Spain). Marín-Martínez F, Ruiz-González MC, Calvo-Sánchez C, et al. J Investig Allergol Clin Immunol. 2008;18(Suppl 2):137-143. PMC: PMC2377138.